Circulating Non-coding RNAs in Recurrent and Metastatic Ovarian Cancer

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582568

Authors

Heidi Schwarzenbach

Peter B Gahan

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer has a poor outcome because it is usually detected at advanced tumor stages, and the majority of the patients develop disease relapse as a result of chemotherapy resistance. This most lethal gynecological malignancy metastasizes within the peritoneal fluid or ascites to pelvic and distal organs. In ovarian cancer progression and metastasis, small non-coding RNAs (ncRNAs), including long noncoding RNAs and microRNAs have been recognized as important regulators. Their dysregulation modulates gene expression and cellular signal pathways and can be detected in liquid biopsies. In this review, we provide an overview on circulating plasma and serum ncRNAs participating in tumor cell migration and invasion, and contributing to recurrence and metastasis of ovarian cancer. We will also discuss the development of potential, novel therapies using ncRNAs as target molecules or tumor markers for ovarian cancer.

Citing Articles

Interplay of microRNAs and circRNAs in Epithelial Ovarian Cancer.

Schwarzenbach H Noncoding RNA. 2024; 10(5).

PMID: 39452837 PMC: 11510331. DOI: 10.3390/ncrna10050051.

Prognostic significance of non-coding RNAs related to the tumorigenic epithelial-mesenchymal transition (EMT) process among ovarian cancer patients: A systematic review and meta-analysis.

Khaboushan A, Salimian S, Mehraban S, Bahramy A, Zafari N, Kajbafzadeh A Heliyon. 2024; 10(16):e35202.

PMID: 39253159 PMC: 11382180. DOI: 10.1016/j.heliyon.2024.e35202.

Role of different non-coding RNAs as ovarian cancer biomarkers.

Beg A, Parveen R, Fouad H, Yahia M, Hassanein A J Ovarian Res. 2022; 15(1):72.

PMID: 35715825 PMC: 9206245. DOI: 10.1186/s13048-022-01002-3.

References

Li Z, Huang C, Bao C, Chen L, Lin M, Wang X . Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015; 22(3):256-64. DOI: 10.1038/nsmb.2959. View

Meng L, Liu B, Ji R, Jiang X, Yan X, Xin Y . Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett. 2019; 17(2):2031-2039. PMC: 6341806. DOI: 10.3892/ol.2018.9854. View

Gasparri M, Besharat Z, Farooqi A, Khalid S, Taghavi K, Besharat R . MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. J Cancer Res Clin Oncol. 2018; 144(12):2313-2318. DOI: 10.1007/s00432-018-2737-y. View

Lungwitz U, Breunig M, Blunk T, Gopferich A . Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005; 60(2):247-66. DOI: 10.1016/j.ejpb.2004.11.011. View

Song K, Lv T, Chen Y, Diao Y, Yao Q, Wang Y . Emodin inhibits TGF-β2 by activating the FOXD3/miR‑199a axis in ovarian cancer cells in vitro. Oncol Rep. 2018; 39(5):2063-2070. PMC: 5928761. DOI: 10.3892/or.2018.6301. View

Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View

Tay Y, Kats L, Salmena L, Weiss D, Tan S, Ala U . Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011; 147(2):344-57. PMC: 3235920. DOI: 10.1016/j.cell.2011.09.029. View

Narberhaus F, Waldminghaus T, Chowdhury S . RNA thermometers. FEMS Microbiol Rev. 2006; 30(1):3-16. DOI: 10.1111/j.1574-6976.2005.004.x. View

Pasquinelli A . MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4):271-82. DOI: 10.1038/nrg3162. View

10.

Qiu J, Lin X, Tang X, Zheng T, Lin Y, Hua K . Exosomal Metastasis‑Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer. Int J Biol Sci. 2018; 14(14):1960-1973. PMC: 6299373. DOI: 10.7150/ijbs.28048. View

11.

Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X . Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Pathol Oncol Res. 2018; 24(4):739-744. DOI: 10.1007/s12253-018-0392-x. View

12.

Lorenz C, Hadwiger P, John M, Vornlocher H, Unverzagt C . Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett. 2004; 14(19):4975-7. DOI: 10.1016/j.bmcl.2004.07.018. View

13.

Ma X, Wang J, Wang J, Ma C, Wang X, Liu F . Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genomics. 2015; 16:676. PMC: 4559210. DOI: 10.1186/s12864-015-1881-x. View

14.

Zou J, Liu L, Wang Q, Yin F, Yang Z, Zhang W . Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res. 2017; 9(3):1357-1368. PMC: 5376026. View

15.

Wang Y, Wang Z . Efficient backsplicing produces translatable circular mRNAs. RNA. 2014; 21(2):172-9. PMC: 4338345. DOI: 10.1261/rna.048272.114. View

16.

Schwarzenbach H, da Silva A, Calin G, Pantel K . Data Normalization Strategies for MicroRNA Quantification. Clin Chem. 2015; 61(11):1333-42. PMC: 4890630. DOI: 10.1373/clinchem.2015.239459. View

17.

Smith J, Alvarez-Dominguez J, Kline N, Huynh N, Geisler S, Hu W . Translation of small open reading frames within unannotated RNA transcripts in Saccharomyces cerevisiae. Cell Rep. 2014; 7(6):1858-66. PMC: 4105149. DOI: 10.1016/j.celrep.2014.05.023. View

18.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

19.

Schneider T, Bindereif A . Circular RNAs: Coding or noncoding?. Cell Res. 2017; 27(6):724-725. PMC: 5518877. DOI: 10.1038/cr.2017.70. View

20.

Li D, Luo Y, Gao Y, Yang Y, Wang Y, Xu Y . piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med. 2016; 38(3):927-36. DOI: 10.3892/ijmm.2016.2671. View